Loading…
Loading…
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.
TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.
Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients
TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.
TG Therapeutics Inc. (NASDAQ:TGTX) shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for TGTX and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.